BOSTON, SHANGHAI and SUZHOU – August 19, 2026, SanegeneBio, a clinical-stage biotechnology company developing innovative RNAi therapeutics, announced today the appointment of two accomplished industry veterans to its Executive Team. Yuyan Jin, Ph.D. has been appointed to serve as the Company’s Chief Development Officer (CDO).